Drug metabolism in human liver microsomes assessed as (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation at 10 uM after 120 mins by LC-MS/MS analysis
Drug metabolism in human liver S9 fraction assessed as (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation at 10 uM after 120 mins by LC-MS/MS analysis
Drug metabolism in human liver microsomes assessed as (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation after 120 mins by LC-MS/MS analysis
Intrinsic clearance in human liver microsomes assessed as (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation by measuring Vmax/Km per nmol of enzyme after 120 mins by LC-MS/MS analysis
Drug metabolism in human liver microsomes assessed as (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation per nmol of enzyme at 25 uM after 120 mins by LC-MS/MS analysis
Activity of human recombinant CYP3A4 assessed as enzyme-mediated (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation per nmol of enzyme at 25 uM after 120 mins by LC-MS/MS analysis
Activity of human recombinant CYP4F12 assessed as enzyme-mediated 2-hydroxyethyl (1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-ylcarbamate formation at 25 uM after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP3A5 assessed as enzyme-mediated (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation at 25 uM after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP1A2 assessed as enzyme-mediated (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation at 25 uM after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP4F3A assessed as enzyme-mediated (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation at 25 uM after 120 mins by LC-MS/MS analysis in presence of NADPH